Ciruelos, Eva <br/><br/>
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.  [electronic resource] 

 -  The oncologist  11 2019 
 - e1024-e1033 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1549-490X 
<br/><br/><label>Standard No.: </label>10.1634/theoncologist.2017-0664  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Albumins--administration & dosage<br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Genetic Predisposition to Disease<br/>Humans<br/>Middle Aged<br/>Paclitaxel--administration & dosage<br/>Polymorphism, Genetic<br/>Polyneuropathies--chemically induced<br/>Quality of Life<br/>Receptor, ErbB-2--metabolism<br/>Receptors, Eph Family--genetics